PALM BEACH, Florida, April 5, 2018 /PRNewswire/ --
Marketnewsupdates.com News Commentary
HealthCanada is projecting that cannabis demand will reach one million kilograms per year by the end of 2018. Cannabis supply currently sits at an estimated 300,000 kilograms. This represents a projected 700,000 kilogram supply
The Race To Meet Demand Is On
Cannabis companies are working to meet Health Canada's projected supply shortfall. The cannabis stocks that have soared so far are the ones belonging to companies that have licenses and the production capacity to grow the plants.
At a current market cap of $79 million and trading at $0.86 per share, RavenQuest Biomed Inc. is primed to be one of the new competitors to make moves for mass cannabis production. The company is trading at a fractional valuation compared to a giant like Aurora Cannabis that is valued at over $3 billion. Aurora's stock reached a high of $12.30 this year, and is currently trading at $7.50.
What will be key is the numbers surrounding square footage space available for expansion. With all its recent industry acquisitions, RavenQuest BioMed Inc. could soon be counted among industry giants like Cronos Group and Aurora Cannabis. In addition to strategically gaining ground by acquiring growing facilities, RavenQuest BioMed Inc. has already proven it can outproduce common flat-table growing spaces with its circular growing technology. Their orbital gardens can produce more grams per square foot than any producer in the cannabis industry- up to 1,500 grams, where a typical flatbed environment produces approximately 130 grams. That's a production increase of 1,500 percent.
Overall, the company's continuously expanding growing operations and healthy cash reserves place them in a unique equity position. Growth at this capacity could have cannabis investors seeing green in the near future. Last month the company completed the final tranche of $26.4 million in private financing.
Building The Biggest Cannabis Farms In The World
RavenQuest BioMed Inc. looks set to join the industry titans as they have acquired more licensing and growing capacity than anyone in the country on Indigenous lands. The company struck a deal with Alberta's Fort McMurray First Nation 468 late last year to take the lead on licensing, engineering and architecture for a 24,000-square-foot licensed growing facility that is set to open in 2019. This partnership recently evolved into an MOU which would give RavenQuest a 30% stake in a 10x expanded project at 250,000 square feet, which will make it one of the largest cannabis farms in the world, all on tax-advantaged sovereign Indigenous land.
This is a significant competitive advantage because it will open up opportunities to rapidly expand production in the future, which on its own could potentially make RavenQuest BioMed Inc. uniquely suited to rapidly meet demand shortfalls.
Potential Comparables: Cronos Group Inc. (TSX-V: CRON) (NASDAQ: CRON) - Cronos Group, the first cannabis stock listed on the Nasdaq, operates two licensed producers regulated under Health Canada's ACMPR: Peace Naturals Project (Ontario), which was the first non-incumbent medical cannabis license granted by Health Canada, and Original British Columbia, based in the Okanagan Valley. The company has multiple international production and distribution platforms, including Germany, Israel and Australia.
Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF) - Aurora Cannabis is a licensed producer of medical cannabis with a 55,200-square-foot facility in Mountain View County, Alberta, and operates another 40,000-square-foot facility known as Aurora Vie in Pointe-Claire, Quebec. Recently, Aurora entered an agreement to buy CanniMed Therapeutics Inc., another Canadian-based medical cannabis company.
OrganiGram Holdings Inc. (TSX-V: OGI) (OTCQB: OGRMF) -
Organigram Inc. is a licensed producer of medical marijuana in Canada. The company is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada. Its portfolio includes dry cannabis and cannabis oil, along with accessories like vaporizers.
Emblem Corp. (TSX-V: EMC) (OTC: EMMBF) - Emblem, through its wholly owned subsidiary Emblem Cannabis Corp., is a fully integrated licensed producer and distributor of medical cannabis under Health Canada's ACMPR. Led by a team of cannabis experts and former healthcare and pharma executives, it has three distinct verticals - cannabis production, patient education centre and pharmaceutical dosage form development.
Cannabis Developments Drawing Investor Attention
The estimated $8 billion cannabis industry looks set to keep growing as legalization looms. The race is on for cannabis companies to obtain coveted growing licenses in an industry that could have massive profit potential due to the predicted supply shortfall. RavenQuest BioMed Inc. (CSE: RQB) (OTC: RVVQF) is emerging as an industry leader, rapidly acquiring the space they need to make a big contribution to the national cannabis supply.
For an in-depth look at RavenQuest BioMed Inc. (CSE: RQB) (OTC: RVVQF), visit microsmallcap.com for a full report.
DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty four hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Ravenquest Biomed Inc. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
Media Contact: FN Media Group, LLC firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All